217 related articles for article (PubMed ID: 29588589)
1. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
2. Binding effect of fluorescence labeled glycyrrhetinic acid with GA receptors in hepatocellular carcinoma cells.
Sun YQ; Dai CM; Zheng Y; Shi SD; Hu HY; Chen DW
Life Sci; 2017 Nov; 188():186-191. PubMed ID: 28768154
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
4. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
Li J; Xu H; Ke X; Tian J
J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
7. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
10. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
[TBL] [Abstract][Full Text] [Related]
11. Chemopreventive effect of 18β-glycyrrhetinic acid via modulation of inflammatory markers and induction of apoptosis in human hepatoma cell line (HepG2).
Hasan SK; Siddiqi A; Nafees S; Ali N; Rashid S; Ali R; Shahid A; Sultana S
Mol Cell Biochem; 2016 May; 416(1-2):169-77. PubMed ID: 27116616
[TBL] [Abstract][Full Text] [Related]
12. [18β-glycyrrhetinic acid piperazine derivative A30 inhibits the proliferation of SMMC-7721 hepatoma cells].
Zhong L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Sep; 33(9):1212-1216. PubMed ID: 29089079
[TBL] [Abstract][Full Text] [Related]
13. Construction of redox-sensitive liposomes modified by glycyrrhetinic acid and evaluation of anti-hepatocellular carcinoma activity.
Hu J; Zheng Y; Wen Z; Fu H; Yang X; Ye X; Zhu S; Kang L; Li X; Yang X; Hu Y
Chem Phys Lipids; 2023 May; 252():105292. PubMed ID: 36931583
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma.
Dinh CT; Vu HT; Phan QTH; Nguyen LP; Tran TQ; Van Tran D; Quy NN; Pham DTN; Nguyen DT
J Mater Sci Mater Med; 2022 Oct; 33(10):72. PubMed ID: 36195780
[TBL] [Abstract][Full Text] [Related]
15. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
He ZY; Zheng X; Wu XH; Song XR; He G; Wu WF; Yu S; Mao SJ; Wei YQ
Int J Pharm; 2010 Sep; 397(1-2):147-54. PubMed ID: 20667672
[TBL] [Abstract][Full Text] [Related]
16. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
17. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
18. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
19. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
[TBL] [Abstract][Full Text] [Related]
20. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma.
Li X; Diao W; Xue H; Wu F; Wang W; Jiang B; Bai J; Lian B; Feng W; Sun T; Yu W; Wu J; Qu M; Wang Y; Gao Z
Cancer Lett; 2020 Oct; 489():163-173. PubMed ID: 32592729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
